Cargando…
A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537832/ https://www.ncbi.nlm.nih.gov/pubmed/28686224 http://dx.doi.org/10.3390/nu9070717 |
_version_ | 1783254255817195520 |
---|---|
author | Habs, Michael Binder, Karin Krauss, Stefan Müller, Karolina Ernst, Brigitte Valentini, Luzia Koller, Michael |
author_facet | Habs, Michael Binder, Karin Krauss, Stefan Müller, Karolina Ernst, Brigitte Valentini, Luzia Koller, Michael |
author_sort | Habs, Michael |
collection | PubMed |
description | Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for the general population are under debate. There is a strong safety record for T&HI and additionally epidemiological evidence for the preventive effects of regular tea consumption on cardiovascular events and certain types of cancer. There is no epidemiological evidence, however, for human risks of regular low dose PA exposure. Recommended regulatory PA-threshold values are based on experimental data only, accepting big uncertainties. If a general risk exists through PA contaminated T&HI, it must be small compared to other frequently accepted risks of daily living and the proven health effects of T&HI. Decision making should be based on a balanced riskbenefit analysis. Based on analyses of the scientific data currently available, it is concluded that the benefits of drinking T&HI clearly outweigh the negligible health risk of possible PA contamination. At the same time, manufacturers must continue their efforts to secure good product quality and to be transparent on their measures of quality control and risk communication. |
format | Online Article Text |
id | pubmed-5537832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55378322017-08-04 A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions Habs, Michael Binder, Karin Krauss, Stefan Müller, Karolina Ernst, Brigitte Valentini, Luzia Koller, Michael Nutrients Review Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for the general population are under debate. There is a strong safety record for T&HI and additionally epidemiological evidence for the preventive effects of regular tea consumption on cardiovascular events and certain types of cancer. There is no epidemiological evidence, however, for human risks of regular low dose PA exposure. Recommended regulatory PA-threshold values are based on experimental data only, accepting big uncertainties. If a general risk exists through PA contaminated T&HI, it must be small compared to other frequently accepted risks of daily living and the proven health effects of T&HI. Decision making should be based on a balanced riskbenefit analysis. Based on analyses of the scientific data currently available, it is concluded that the benefits of drinking T&HI clearly outweigh the negligible health risk of possible PA contamination. At the same time, manufacturers must continue their efforts to secure good product quality and to be transparent on their measures of quality control and risk communication. MDPI 2017-07-07 /pmc/articles/PMC5537832/ /pubmed/28686224 http://dx.doi.org/10.3390/nu9070717 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Habs, Michael Binder, Karin Krauss, Stefan Müller, Karolina Ernst, Brigitte Valentini, Luzia Koller, Michael A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title | A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title_full | A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title_fullStr | A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title_full_unstemmed | A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title_short | A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions |
title_sort | balanced risk–benefit analysis to determine human risks associated with pyrrolizidine alkaloids (pa)—the case of tea and herbal infusions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537832/ https://www.ncbi.nlm.nih.gov/pubmed/28686224 http://dx.doi.org/10.3390/nu9070717 |
work_keys_str_mv | AT habsmichael abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT binderkarin abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT kraussstefan abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT mullerkarolina abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT ernstbrigitte abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT valentiniluzia abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT kollermichael abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT habsmichael balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT binderkarin balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT kraussstefan balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT mullerkarolina balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT ernstbrigitte balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT valentiniluzia balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions AT kollermichael balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions |